Predict your next investment

Private Equity
aurelia-pe.de

See what CB Insights has to offer

Investments

16

Portfolio Exits

4

Funds

1

About Aurelia Private Equity

AURELIA PRIVATE EQUITY participates in innovative technology companies in the areas of information and telecommunications technology, medicine technology, and industry innovations. They aim to invest in businesses which are led by an excellent management and have scalable products with clear competitive advantages

Aurelia Private Equity Headquarter Location

Kurhessenstr. 1-3

Frankfurt, 60431,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aurelia Private Equity

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Aurelia Private Equity in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Aurelia Private Equity News

Third round financing for GILUPI GmbH with Aurelia Private Equity, Brandenburg Capital (BFBII), KfW Bankengruppe and High-Tech Gründerfonds

Apr 29, 2016

Press Third round financing for GILUPI GmbH with Aurelia Private Equity, Brandenburg Capital (BFBII), KfW Bankengruppe and High-Tech Gründerfonds GILUPI GmbH is an innovative company developing and producing medical devices for the in vivo isolation of rare cells out of the circulating blood. GILUPI will use the current financing mainly for the CE-certification and the subsequent introduction into the market of its patented medical detector. The early approval of the device according to the MPG (Medical Devices Act) is essential for achieving the economic objectives of GILUPI. New innovative products for isolating rare cells out of the blood are currently of high interest on the market for medical products. Due to the long phases of product development and approval and the market life cycles of products which are becoming shorter an immediate entry into the market is important. Therefore, the first GILUPI product for clinical research, “Nanodetector Cancer 01”, is intended to get its approval in 2011. Further approvals, possibly in combination with in vitro diagnostic kits for the analysis of isolated cells, will be applied for in the fields of cancer and prenatal diagnostics in the years to come. For the production and the market entry of a medical product the certification of the producer according to ISO 13485 and the CE-certification of the device are mandatory. The early detection of cancer is still the most decisive factor in its successful treatment, its follow-up and the improvement of the patient´s quality of life. The value of today´s diagnostic methods is limited because some of the methods rely on small specimen volumes from which conclusions concerning the status of a whole organ or the complete organism are being drawn. In addition many of these methods put the patients under a heavy physical or mental burden. This situation is emphasizing the necessity for developing new methods of improved diagnostic value. The new GILUPI medical device is an innovative approach combining the in vivo isolation of cells and their subsequent in vitro analysis. The nanodetector makes it possible to specifically isolate tumor cells out of a patient´s circulating blood by the predetermined selectivity of the antibodies bound on the nanodetector. These cells can then be used for the analysis of their genetic status and for determining genetic aberrations. In several clinical trials tumor cells were isolated by this nanodetector with a detection rate of more than 90 %. “In addition to our unique technological platform a further strength of GILUPI is its team of investors. I am very proud that besides the ERP Startfonds all of the first investors have joined again for the next round of financing GILUPI´s efforts with 3.6 Million Euros and are supporting our course of expansion”, the founder and CEO of GILUPI, Klaus Lücke, is saying and continues “with this new round we are not only implementing our entry into the market but we will also establish the structure for future cooperations”. It is the objective to improve the current nanodetector further and to use it for the early detection of several cancers, for evaluating therapy effects, the follow-up and for predicting the prognosis of the disease. For a similar medical device designed for prenatal diagnostics the in vivo proof of concept was achieved. About GILUPI GmbH GILUPI – founded in 2006 and located in the Science Park of Potsdam-Golm – developed a patented medical detector. The nanodetector consists of a thin gold coated wire which is covered with threads of a nanopolymer in order to make the tip of the wire smooth and biocompatible. The polymer layer is simultaneously serving as support for the tight binding of antibodies against specific molecules on cells which are to be isolated out of the circulating blood. These antibodies are able to bind these molecules and thus capture the cells. For further information, please turn to www.gilupi.com About AURELIA PRIVATE EQUITY GmbH Aurelia Private Equity based in Frankfurt am Main invests into fast growing technology companies in the sectors of internet, media, telecommunication, software, industry and life sciences. We look for enterprises with an experienced management, technological advantage and a high scaling potential. Aurelia Private Equity GmbH

Aurelia Private Equity Investments

16 Investments

Aurelia Private Equity has made 16 investments. Their latest investment was in GILUPI as part of their Series C on January 1, 2011.

CBI Logo

Aurelia Private Equity Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/13/2011

Series C

GILUPI

$4.8M

Yes

Brandenburg Kapital, High-Tech Grunderfonds, and KfW

1

7/17/2010

Series C

MerLion Pharmaceuticals

$7M

Yes

Aravis Ventures, EDBI, HeidelbergCapital, and VI Partners

11/25/2009

Growth Equity

Hematris Wound Care

$2.7M

Yes

KfW

1

7/8/2008

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/1/2008

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/13/2011

7/17/2010

11/25/2009

7/8/2008

1/1/2008

Round

Series C

Series C

Growth Equity

Series A

Unattributed VC

Company

GILUPI

MerLion Pharmaceuticals

Hematris Wound Care

Subscribe to see more

Subscribe to see more

Amount

$4.8M

$7M

$2.7M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Brandenburg Kapital, High-Tech Grunderfonds, and KfW

Aravis Ventures, EDBI, HeidelbergCapital, and VI Partners

KfW

Sources

1

1

10

10

Aurelia Private Equity Portfolio Exits

4 Portfolio Exits

Aurelia Private Equity has 4 portfolio exits. Their latest portfolio exit was GILUPI on December 14, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/14/2016

Acquired

Hebei Viroad Biotechnology

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

12/14/2016

00/00/0000

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Hebei Viroad Biotechnology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

Aurelia Private Equity Fund History

1 Fund History

Aurelia Private Equity has 1 fund, including Aurelia I Technology Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2001

Aurelia I Technology Fund

Early-Stage Venture Capital

$26.76M

1

Closing Date

12/31/2001

Fund

Aurelia I Technology Fund

Fund Type

Early-Stage Venture Capital

Status

Amount

$26.76M

Sources

1

Aurelia Private Equity Team

3 Team Members

Aurelia Private Equity has 3 team members, including current Managing Partner, Jã¼rgen Leschke.

Name

Work History

Title

Status

Jã¼rgen Leschke

Managing Partner

Current

Johann-wolfgang Posselt

Managing Partner

Current

Wolfgang Posselt

TBG

Managing Partner

Current

Name

Jã¼rgen Leschke

Johann-wolfgang Posselt

Wolfgang Posselt

Work History

TBG

Title

Managing Partner

Managing Partner

Managing Partner

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.